May 3 BioPharma Summit Polling Questions

Live polling on May 3 will be open only during each panel and will close one minute after the panel is over. Poll results will be announced before the start of next panel. We encourage you to cast your answer in the polls. Your answers will be anonymous. We suggest you read the polling questions beforehand.

1. BioPharma R&D and Global Supply Chain agenda at G20

What would have the biggest impact on helping to mitigate the next pandemic?

• Building more adaptable global supply chains for drugs and vaccines.
• Greater use of advanced purchasing agreements and related mechanisms to encourage industry R&D.
• More public-private partnerships and pre-competitive industry collaborations. 

2. Clinical Trials Opportunities in India

What do you most expect to see over the next year?

• More clinical trials conducted in India by Western biopharma companies than in prior year.
• Roughly the same number of clinical trials conducted in India by Western biopharma companies.
• Less clinical trials conducted in India by Western biopharma companies.

3. BioPharma Industry & Investment Outlook

What do you most expect to see over the next year?

• Capital markets will start to open by the end of the year
• New company formation will plummet
• The IRA overhang will cause companies to reconfigure their pipelines
• Two or more women will be appointed as CEO of major pharma companies

4. Joaquin Duato, Chairman & CEO, Johnson & Johnson’s Fireside Chat

There will be roughly equal numbers of women and men in pharma executive teams in:

• 5 years
• 10 years
• 20 years
• Never

5. After Rob Califf, FDA Fireside chat

In the next year, the number of accelerated approvals will:

• Decrease
• Stay the same
• Increase

6. Industry Academic Partnerships

Academics have improved their ability to perform reproducible research to industry standards

• Not at all
• A small amount
• A large amount
• Totally

7. Oncology

What will cause the biggest change in clinical trials in oncology?

• Dose optimization guidance
• Accelerated approval guidance
• FDA guidelines regarding clinical trial diversity

8. Digital & Data Science in Healthcare

Where are digital technologies likely to make their greatest impact on drug development in the near term?

• Digital endpoints
• Digital therapeutics
• Patient recruitment
• Trial decentralization
• Real-world evidence collection and interpretation

9. After Dr. Albert Bourla, Chairman and CEO, Pfizer’s Fireside chat

mRNA will become the major anti-vaccine technology for in infectious disease

• Agree
• Disagree

10. R&D Strategies and Trends (Poll will take place during 12 pm break)

What disease area is likely to see the biggest step-change in the next 1-2 years:

• Alzheimer’s disease
• Obesity
• Infectious disease
• Inflammation